

Inmaculada Hernandez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2451156/publications.pdf>

Version: 2024-02-01

94
papers

1,990
citations

279778

23
h-index

276858

41
g-index

97
all docs

97
docs citations

97
times ranked

2774
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Bleeding With Dabigatran in Atrial Fibrillation. <i>JAMA Internal Medicine</i> , 2015, 175, 18.	5.1	249
2	Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 854.	7.4	124
3	Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries. <i>JAMA Network Open</i> , 2018, 1, e180919.	5.9	115
4	Evaluation of Frequency of Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among Medicare Beneficiaries. <i>JAMA Network Open</i> , 2020, 3, e209132.	5.9	106
5	Total Costs of Chimeric Antigen Receptor T<i>-</i>Cell Immunotherapy. <i>JAMA Oncology</i> , 2018, 4, 994.	7.1	93
6	Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 1816-1822.e2.	1.5	82
7	Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 1813-1819.	1.6	80
8	Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: An umbrella review. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1155-1165.	3.0	67
9	Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program. <i>JAMA Network Open</i> , 2020, 3, e2020969.	5.9	66
10	Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 37-47.	2.2	51
11	Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella review. <i>Preventive Medicine</i> , 2018, 115, 145-155.	3.4	49
12	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. <i>JAMA Network Open</i> , 2021, 4, e2114501.	5.9	49
13	Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2019, 8, e011427.	3.7	48
14	Pricing of monoclonal antibody therapies: higher if used for cancer?. <i>American Journal of Managed Care</i> , 2018, 24, 109-112.	1.1	45
15	Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 159-166.	2.0	42
16	The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs. <i>Health Affairs</i> , 2019, 38, 76-83.	5.2	42
17	Using predictive analytics and big data to optimize pharmaceutical outcomes. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1494-1500.	1.0	40
18	Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data. <i>Journal of the National Medical Association</i> , 2020, 112, 103-108.	0.8	34

#	ARTICLE	IF	CITATIONS
19	Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition. <i>JAMA Network Open</i> , 2019, 2, e1917379.	5.9	31
20	Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D. <i>JAMA Neurology</i> , 2019, 76, 1386.	9.0	29
21	Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 281-292.	0.9	28
22	Optimizing the Role of Community Pharmacists in Managing the Health of Populations: Barriers, Facilitators, and Policy Recommendations. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 995-1000.	0.9	26
23	Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1627.	7.4	25
24	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. <i>Thrombosis Research</i> , 2017, 150, 123-130.	1.7	22
25	Latent Classes of Adherence to Oral Anticoagulation Therapy Among Patients With a New Diagnosis of Atrial Fibrillation. <i>JAMA Network Open</i> , 2020, 3, e1921357.	5.9	21
26	Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 199-207.	2.2	19
27	Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 1276-1284.	2.6	19
28	Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 247-254.	0.9	18
29	Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications. <i>JAMA Network Open</i> , 2019, 2, e1910626.	5.9	18
30	Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 2289-2291.	2.0	17
31	Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014. <i>Heart Rhythm</i> , 2019, 16, 1065-1071.	0.7	17
32	Changes in Drug Pricing After Drug Shortages in the United States. <i>Annals of Internal Medicine</i> , 2019, 170, 74.	3.9	16
33	Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data. <i>JAMA Internal Medicine</i> , 2015, 175, 1245.	5.1	14
34	A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 319-325.	1.8	14
35	Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 69-75.	1.6	12
36	Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications. <i>Value in Health</i> , 2019, 22, 1266-1274.	0.3	12

#	ARTICLE	IF	CITATIONS
37	The Skyrocketing Cost of Rectal Indomethacin. <i>JAMA Internal Medicine</i> , 2020, 180, 631.	5.1	12
38	Marked Increase in Sales of Erectile Dysfunction Medication During COVID-19. <i>Journal of General Internal Medicine</i> , 2021, 36, 2912-2914.	2.6	12
39	Drug Shortages in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 819.	7.4	11
40	Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 333-343.	2.2	11
41	The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 766-774.e6.	1.5	11
42	Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy—Reply. <i>JAMA Oncology</i> , 2018, 4, 1785.	7.1	10
43	Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 317-325.	2.2	10
44	Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors. <i>JAMA Internal Medicine</i> , 2019, 179, 713.	5.1	10
45	Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010–2016. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 471-479.	2.2	9
46	Time to Reconsider Dabigatran 110Âmg in the USA. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 307-309.	2.2	8
47	Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 644-651.	1.9	8
48	Risk factors for cardiovascular events of antedementia drugs in Alzheimer's disease patients. <i>Journal of Clinical Gerontology and Geriatrics</i> , 2016, 7, 77-82.	0.7	7
49	Teaching About the Health Care Industry Through Gamification. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 6422.	2.1	7
50	Association of Antedementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease. <i>JAMA Network Open</i> , 2019, 2, e190213.	5.9	7
51	Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 126, 29-36.	1.6	7
52	Revisiting Outcomes—Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab. <i>JAMA Internal Medicine</i> , 2017, 177, 1388.	5.1	6
53	Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 154-159.	0.9	6
54	Comparing Adoption of Breakthrough and “Me-too” Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors. <i>Journal of Pharmaceutical Innovation</i> , 2017, 12, 105-109.	2.4	5

#	ARTICLE	IF	CITATIONS
55	Interpreting COVID-19 Test Results: a Bayesian Approach. Journal of General Internal Medicine, 2020, 35, 2490-2491.	2.6	5
56	Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	4.4	5
57	Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis. American Heart Journal Plus, 2022, 13, 100096.	0.6	5
58	COVID-19 and Anticoagulation for Atrial Fibrillation: An Analysis of US Nationwide Pharmacy Claims Data. Journal of the American Heart Association, 2021, 10, e023235.	3.7	5
59	Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis. Journal of Evaluation in Clinical Practice, 2015, 21, 840-847.	1.8	4
60	Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012. Gerontology and Geriatric Medicine, 2017, 3, 233372141770494.	1.5	4
61	Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline. Journal of the American Heart Association, 2018, 7, .	3.7	4
62	Comparing state, regional, and local variation in concurrent opioid and benzodiazepine use. Drug and Alcohol Dependence, 2018, 191, 141-144.	3.2	4
63	Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas. American Journal of Cardiology, 2020, 130, 64-69.	1.6	4
64	Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies. JAMA Dermatology, 2020, 156, 1136.	4.1	4
65	Association between opioid dose escalation and time to death in a comfort measures only population. American Journal of Health-System Pharmacy, 2021, 78, 203-209.	1.0	4
66	Pricing of Monoclonal Antibodies in the United States. Global Journal on Quality and Safety in Healthcare, 2018, 1, 4-5.	0.5	4
67	Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. Diabetes Research and Clinical Practice, 2022, 187, 109855.	2.8	4
68	Lowering the P Value Threshold. JAMA - Journal of the American Medical Association, 2018, 320, 935.	7.4	3
69	Number of manufacturers and generic drug pricing from 2005 to 2017. American Journal of Managed Care, 2019, 25, 348-352.	1.1	3
70	Identifying Patients at Risk of Acute Kidney Injury Among Medicare Beneficiaries With Type 2 Diabetes Initiating SGLT2 Inhibitors: A Machine Learning Approach. Frontiers in Pharmacology, 2022, 13, 834743.	3.5	3
71	Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes. Health Services Research, 2022, 57, 1136-1144.	2.0	3
72	Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence. BMC Medicine, 2018, 16, 238.	5.5	2

#	ARTICLE	IF	CITATIONS
73	Statins for Primary Prevention of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 72.	3.9	2
74	Impact of direct-to-consumer drug advertising during the Super Bowl on drug utilization. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1136-1139.	3.0	2
75	Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 112-117.	0.9	2
76	Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 581-583.	2.2	2
77	A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 565-573.	0.9	2
78	Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020. <i>JAMA Network Open</i> , 2021, 4, e2112044.	5.9	2
79	Relationships between provider-led health plans and quality, utilization, and satisfaction. <i>American Journal of Managed Care</i> , 2018, 24, 628-632.	1.1	2
80	Drug Shortages and Group Purchasing Organizationsâ€™ Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 809.	7.4	1
81	Estimating Discounts for Top Spending Drugs in Medicare Part D. <i>Journal of General Internal Medicine</i> , 2020, 36, 2503-2505.	2.6	1
82	Risk Factors for Cardiovascular Events in Patients on Antidementia Medications. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2020, 35, 153331752092238.	1.9	1
83	Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 573-580.	2.2	1
84	The Costs of Delayed Generic Drug Entry: Evidence from a Controversial Prostate Cancer Drug Patent. <i>Journal of General Internal Medicine</i> , 2021, , 1.	2.6	1
85	Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1500-1502.	0.9	1
86	Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation. <i>Frontiers in Public Health</i> , 2021, 9, 780185.	2.7	1
87	Incidence of fracture events with teriparatide: role of study design. <i>Osteoporosis International</i> , 2015, 26, 2219-2219.	3.1	0
88	Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine. <i>JAMA Internal Medicine</i> , 2018, 178, 873.	5.1	0
89	Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data. <i>Journal of General Internal Medicine</i> , 2019, 34, 1682-1684.	2.6	0
90	Drug Prices, Rebates, and Discountsâ€™ Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 399.	7.4	0

#	ARTICLE	IF	CITATIONS
91	Abstract MP18: Trajectories of Oral Anticoagulation Adherence After First Atrial Fibrillation Diagnosis. <i>Circulation</i> , 2019, 139, .	1.6	0
92	Decomposition of Expenditures for Insulins Across the Distribution Chain—Insights Into Rising Prices?. <i>JAMA Health Forum</i> , 2021, 2, e212258.	2.2	0
93	Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1672-1679.	0.9	0
94	Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 266-274.	0.9	0